A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment.
Robin LochbaumSusanne TrainottiThomas K HoffmannJens GreveJanina HahnPublished in: The Journal of dermatological treatment (2023)
This is one of the first descriptions of the clinical outcomes as a response to prophylactic treatment with lanadelumab in HAE-nC1-INH patients with a known mutation. The therapeutic management of HAE-1 and HAE-2 should also be the basis of HAE-nC1-INH, including prophylaxis.
Keyphrases